The study involved just 12 patients and hence the
Alzheimer's Association has expressed concern.
"People with Alzheimer's and their families may
place undue value on this new finding based on the dramatic language used in
its description and the apparent immediate effect," the group said.
"We need to see work in other laboratories by scientists without financial
interest in the product."
Dr. Scott Turner,
incoming director of the Memory Disorders Program at Georgetown University
Medical Center said there must be double-blind, placebo-controlled, randomized
clinical trials before any judgment is passed.